In light of these observations, it is tempting to speculate that a signature of Bcl-2pSer70, STAT3 phosphorylation (STAT3pTyr705 and/or pSer727), active Rac1, and low SOD1 (indicative of higher O2•−) may be associated with disease severity and/or poor outcome in patients with lymphomas and other hematopoietic malignancies or could be beneficial in stratifying malignancies where Bcl-2 overexpression presents a therapeutic challenge. Here, BCL2 is linked to lymphoma.